Physician profile
Stephen D Maberry
NPI 1093754756
$6,406.28
in general payments reported to CMS, 2019-2025
28 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 77% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $222 · 2021: $308 · 2022: $785 · 2023: $1,834 · 2024: $1,429 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,395.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imbed Biosciences INC. | $779.46 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $509.66 | 2020-2024 | Targretin, Arazlo |
| Lilly USA, LLC | $434.15 | 2019-2024 | Olumiant |
| Abbvie INC. | $394.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $339.99 | 2023-2025 | Libtayo, Dupixent |
| Almirall LLC | $304.43 | 2019-2023 | Klisyri |
| Incyte Corporation | $288.82 | 2022-2024 | Opzelura |
| Dermavant Sciences, INC. | $271.20 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $259.38 | 2023-2024 | Ycanth |
| Ucb, INC. | $251.89 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.49 | 2023-2024 | Spevigo |
| Convatec INC. | $236.98 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $226.26 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $224.92 | 2024-2025 | |
| Bioventus LLC | $206.33 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $183.19 | 2021 | |
| Pfizer INC. | $158.84 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $146.31 | 2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $145.72 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $142.60 | 2025 | Nemluvio |
| Genentech USA, INC. | $120.72 | 2019 | |
| Kerecis Limited | $119.16 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Biofrontera INC. | $116.88 | 2019 | |
| Sun Pharmaceutical Industries INC. | $106.06 | 2023 | Ilumya |
| Kyowa Kirin, INC. | $91.60 | 2024 | Poteligeo |
| Aclaris Therapeutics, INC. | $46.29 | 2019 | |
| Biotissue Holdings INC. | $39.54 | 2023 | |
| Fidia Pharma USA INC. | $17.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Maberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.